The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...
A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...
The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...
Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...
Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback